Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimensKen Saijo, Chikashi Ishioka, Sakura Taniguchi et al.|Frontiers in Oncology|2023Cited by 10
Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell CarcinomaReio Ueta, Chikashi Ishioka, Hiroo Imai et al.|Oncology|2023Cited by 5
Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks Is Associated with Favorable Outcomes of Patients Treated with VEGF Pathway InhibitorsYuya Yoshida, Chikashi Ishioka, Masanobu Takahashi et al.|Internal Medicine|2024Cited by 4